A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.

Y N Vashisht GopalSeth T GammonRishika PrasadBarbara KnightonFederica Pisaneschi Jason Roszik Ningping FengSarah JohnsonSnigdha PramanikJessica SudderthDawen SuiCourtney W HudgensGrant M FischerWanleng DengAlexandre Reuben Weiyi PengJian WangJennifer Leigh McQuade Michael A DaviesMaria E Di FrancescoJoe MarszalekDavid Piwnica-WormsRalph J DeBerardinis

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Targeting OxPhos with OPi has significant antitumor activity in MAPKi-resistant, BRAF-mutant melanomas, and merits further clinical investigation as a potential new strategy to overcome intrinsic and acquired resistance to MAPKi in patients.

Keyphrases

oxidative stress
end stage renal disease
signaling pathway
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
pi k akt
peritoneal dialysis
cancer therapy
patient reported outcomes
climate change
cell proliferation
risk assessment
skin cancer